Ratings Transgene

Equities

TNG

FR0005175080

Market Closed - Euronext Paris Other stock markets 11:35:10 2024-04-30 am EDT			5-day change	1st Jan Change
1.24 ^EUR	-0.32%		-6.77%	-9.49%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 3.54 times the sales for the current fiscal year, the company turns out to be overvalued.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TRANSGENE	-9.49%	133M	C+
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B	B+
ARGENX SE	+2.13%	22.28B	B
BIONTECH SE	-14.77%	21.4B	B+
GENMAB A/S	-8.79%	18.14B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.02B	A-
BEIGENE, LTD.	-13.21%	16.09B	B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B	C+
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes